Skip to main content

Table 1 Baseline characteristics and laboratory findings according to BMI groups a

From: Association of body mass index with risk of acute myocardial infarction and mortality in Norwegian male and female patients with suspected stable angina pectoris: a prospective cohort study

 

Total n = 4131

Normal weight n = 1395

Overweight n = 1970

Obese n = 766

p-valueb

Demographic characteristics

     

Male sex, n (%)

2989 (72.4)

959 (68.7)

1517 (77.0)

513 (67.0)

<0.001

Age (years)c

62 (10)

63 (11)

61 (10)

60 (10)

<0.001

Clinical parameters

     

Systolic blood pressure (mmHg)

141 (20.7)

139 (21.0)

142 (20.6)

143 (20.3)

<0.001

Diastolic blood pressure (mmHg)

81.3 (10.4)

79.3 (10.3)

82.0 (10.1)

83.3 (10.7)

<0.001

Left ventricular ejection fraction (%)

64.0 (11.3)

63.7 (11.9)

64.4 (10.7)

63.6 (11.8)

0.08

Cardiovascular risk factors, n (%)

     

Diabetesd

496 (12.0)

123 (8.8)

209 (10.6)

164 (21.4)

<0.001

Current smokere

1061 (25.7)

417 (29.9)

469 (23.9)

175 (22.9)

<0.001

Ex smokerf

1933 (46.9)

571 (40.6)

975 (49.6)

387 (50.7)

<0.001

Family history of coronary heart diseaseg

1253 (31.1)

417 (30.8)

573 (29.7)

263 (35.1)

0.02

Cardiovascular history, n (%)

     

Previous acute myocardial infarction

1670 (40.4)

564 (40.4)

784 (39.8)

322 (42.0)

0.56

Previous cerebrovascular disease

286 (6.9)

100 (7.2)

128 (6.5)

58 (7.6)

0.55

Previous peripheral vascular arterial disease

371 (9.0)

153 (11.0)

148 (7.5)

70 (9.1)

<0.01

Previous percutaneous coronary intervention

794 (19.2)

250 (17.9)

396 (20.1)

148 (19.3)

0.29

Previous coronary artery bypass graft surgery

477 (11.5)

150 (10.8)

238 (12.1)

89 (11.6)

0.49

Extent of coronary artery disease at baseline as assessed by coronary angiography, n (%)

   

No significant coronary artery disease

1030 (24.9)

367 (26.3)

467 (23.7)

196 (25.6)

0.21

1-vessel disease

958 (23.2)

306 (21.9)

482 (24.5)

170 (22.2)

0.18

2-vessel disease

923 (22.3)

308 (22.1)

440 (22.3)

175 (22.8)

0.92

3-vesseldisease

1220 (29.5)

414 (29.7)

581 (29.5)

225 (29.4)

0.99

Comorbidity at baseline, n (%)

     

Pulmonary disease

367 (8.9)

139 (10.0)

140 (7.1)

88 (11.5)

<0.001

Cancer

4 (0.1)

2 (0.1)

1 (0.1)

1 (0.1)

0.66

Medication following baseline coronary angiography, n (%)

    

Acetylsalisylic acid

3376 (81.7)

1114 (79.9)

1638 (83.1)

624 (81.5)

0.05

Statins

3310 (80.1)

1064 (76.3)

1626 (82.5)

620 (80.9)

<0.001

β-blockers

2994 (72.5)

970 (69.5)

1456 (73.9)

568 (74.2)

0.01

ACE inhibitors

858 (20.8)

243 (17.4)

403 (20.5)

212 (27.7)

<0.001

Loop diuretics

447 (10.8)

127 (9.1)

182 (9.2)

138 (18.0)

<0.001

Coronary revascularization following baseline coronary angiography, n (%)

   

Percutaneous coronary intervention

1348 (32.6)

432 (31.0)

663 (33.7)

253 (33.0)

0.26

Coronary artery bypass graft surgery

892 (21.6)

302 (21.6)

438 (22.2)

152 (19.8)

0.39

Biochemical markers

     

Creatinine (μmol/L)

92.6 (31.1)

92.5 (33.4)

93.0 (32.0)

91.8 (23.4)

0.34

eGFR (mL/min)

87.8 (17.3)

86.2 (17.7)

88.5 (16.6)

88.9 (17.8)

<0.001

CRP (mg/L)

3.69 (7.17)

3.34 (7.93)

3.59 (6.67)

4.60 (6.85)

<0.001

Glucose (mmol/L)

6.35 (2.40)

5.93 (2.24)

6.32 (2.28)

7.20 (2.79)

<0.001

HbA1c (mmol/L)

6.22 (1.38)

6.12 (1.28)

6.18 (1.41)

6.51 (1.45)

<0.001

Hemoglobin (g/dL)

14.2 (1.24)

13.9 (1.24)

14.4 (1.18)

14.4 (1.29)

<0.001

ApoA1 (g/L)

1.32 (0.27)

1.37 (0.29)

1.30 (0.25)

1.27 (0.26)

<0.001

ApoB (g/L)

0.90 (0.25)

0.87 (0.24)

0.91 (0.24)

0.93 (0.26)

<0.001

Total cholesterol (mmol/L)

5.07 (1.17)

5.02 (1.14)

5.08 (1.18)

5.10 (1.19)

0.13

LDL cholesterol (mmol/L)

3.09 (1.03)

3.05 (1.02)

3.12 (1.00)

3.11 (1.10)

0.11

HDL cholesterol (mmol/L)

1.29 (0.38)

1.42 (0.43)

1.25 (0.34)

1.17 (0.32)

<0.001

Triglycerides (mmol/L)

1.78 (1.22)

1.43 (0.90)

1.86 (1.28)

2.22 (1.39)

<0.001

Lp(a) (mmol/L)

0.42 (0.39)

0.41 (0.39)

0.43 (0.39)

0.42 (0.39)

0.03

WENBIT intervention trial, n (%)

2560 (62.0)

797 (57.1)

1283 (65.1)

480 (62.7)

<0.001

B6, n (% of WENBIT participants)

1275 (49.8)

394 (49.4)

657 (51.2)

224 (46.7)

<0.01

Folate/B12, n (% of WENBIT participants)

1282 (50.1)

409 (51.3)

649 (50.6)

224 (46.7)

0.04

  1. ACE, angiotensin converting enzyme; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BMI, body mass index; CRP, c-reactive protein; eGFR, esitimated glomerular filtration rate; HDL, high density lipoprotein; LDL, low density lipoprotein; Lp(a), lipoprotein (a).
  2. aNormal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25–29.9 kg/m2) and obese (BMI ≥ 30 kg/m2).
  3. bBased on between group differences calculated by one-way analysis of variance (ANOVA) for continuous variables and Chi squared test for categorical variables.
  4. cMean (SD).
  5. dIncludes DM type 1 and 2.
  6. eSmokers included self-reported current smoking, those who quit smoking within <1 month and patients with plasma cotinine >85 ng/mL.
  7. fPatients reported to have quit smoking > 1 month prior to inclusion.
  8. gIncluded those reporting to have at least one 1st degree relative suffering from CAD before the age of 55 for men and 65 for women.
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us